Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer:A case report and review of literature  

作　　者：Li-Yong Zhang Shao-Jun Cai Bo-Yan Liang Shou-Yi Yan Bo Wang Meng-Yao Li Wen-Xin Zhao 

机构地区：[1]Department of Thyroid Surgery,General Surgery,Minimal Invasive Center,The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid,Fujian Medical University Union Hospital,Fujian Medical University,Fuzhou 350001,Fujian Province,China

出　　处：《World Journal of Clinical Cases》2023年第12期2839-2847,共9页世界临床病例杂志

摘　　要：BACKGROUND Papillary thyroid cancer(PTC)is one of the well-differentiated thyroid tumors.Cutaneous metastasis from differentiated thyroid cancers occurs in<1%of primary thyroid carcinomas but produces the worst survival prognosis.The multi-targeting tyrosine kinase inhibitor anlotinib has been approved to treat refractory advanced non-small-cell lung cancer as well as advanced soft-tissue and clear cell sarcomas in China.CASE SUMMARY In a patient with scalp metastasis caused by PTC,thyroid and skull metastasis tumor sizes were significantly reduced after a trial of neoadjuvant anlotinib therapy for 3 cycles.Anlotinib maintenance medication after thyroidectomy further reduced the metastatic skull tumor size thereby preventing the requirement for craniotomy.CONCLUSION The outcome of the present trial confirmed the potential of anlotinib therapy to treat scalp metastasis induced by PTC and point the way for the treatment of similar diseases in the future.

关 键 词：Papillary thyroid cancer Tyrosine kinase inhibitor Neoadjuvant anlotinib therapy Literature review Case report 

分 类 号：R736.1[医药卫生—肿瘤]